Allworth Financial’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Allworth Financial’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-111	Closed	-$4.76K	–	3878
2024 Q2	$4.76K	Buy	111 +47	+73%	+$1.96K	﹤0.01%	2549
2024 Q1	$2.71K	Hold	64	–	–	﹤0.01%	2695
2023 Q4	$2.71K	Buy	64 +19	+42%	+$546	﹤0.01%	2537
2023 Q3	$983	Buy	+45	New	+$1.13K	﹤0.01%	2856
2023 Q2	–	Sell	-6	Closed	-$147	–	3412
2023 Q1	$147	Hold	6	–	–	﹤0.01%	3063
2022 Q4	$189	Buy	+6	New	+$169	﹤0.01%	2793

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Allworth Financial's CERE Position: Q3 2024 in Review

Allworth Financial sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 111 shares — an estimated $4.76K sold.

Allworth Financial first reported a position in CERE in Q4 2022 and held it in 6 quarters. The position peaked at $4.76K in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Allworth Financial reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Allworth Financial sold 111 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $4.76K.
Allworth Financial first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 6 quarters.
Allworth Financial's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $4.76K in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Allworth Financial's 13F filing for Q3 2024, filed 23 Oct 2024.